Aviso Wealth Management Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Aviso Wealth Management lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 35.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,719 shares of the company's stock after buying an additional 4,081 shares during the quarter. Johnson & Johnson makes up approximately 1.2% of Aviso Wealth Management's portfolio, making the stock its 16th biggest position. Aviso Wealth Management's holdings in Johnson & Johnson were worth $2,273,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in JNJ. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after buying an additional 100 shares during the last quarter. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson during the fourth quarter worth approximately $29,000. RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson in the third quarter valued at approximately $35,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $32,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $38,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded up $0.78 during midday trading on Friday, hitting $163.91. The company had a trading volume of 3,239,447 shares, compared to its average volume of 9,058,966. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The business has a 50-day simple moving average of $158.35 and a two-hundred day simple moving average of $156.23. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The firm has a market capitalization of $395.00 billion, a price-to-earnings ratio of 24.65, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.29 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.03%. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Monday, March 10th. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Wells Fargo & Company reduced their price objective on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Finally, Stifel Nicolaus lowered their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $171.33.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.